Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AutoZone

NextEra Energy

AT&T

White Mountains Insurance Group

The Nasdaq Composite shed almost 1,400 points in a three-day stretch, which decisively pushed this growth-oriented index into correction territory. Heightened volatility on Wall Street is no reason for long-term investors to retreat to the sideline.

Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market

Becton, Dickinson and Co.

PepsiCo

Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.

The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT) The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) SPRING HOUSE, Pa., Aug. 7, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the treatment of alloimmunizeda pregnant individuals at risk of early onset severe (EOS) HDFN have been published in The New England Journal of Medicine (NEJM).

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Abbott Labs

Pfizer

Abbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.

3 Dividend Growth Stocks to Buy Hand Over Fist in August

Visa

Dividend-paying stocks are ideal for outperforming the market or generating passive income. Finding dividend growth stocks, companies that have shown the ability and willingness to raise their distributions over time, providing consistent and growing income to investors, are even more valuable, particularly in this current market.

3 Dividend Growth Stocks to Accumulate on Dips: August Edition

Coca-Cola

Procter & Gamble

In a week where fear, uncertainty, and widespread selling swept the market, three stocks stood out for their resilience: Johnson & Johnson NYSE: JNJ, Coca-Cola NYSE: KO, and Procter & Gamble NYSE: PG.

3 Defensive Stocks Weathering the Market Storm

Walmart

The most recent U.S. jobs report published on Friday, August 2, gave investors a fright, as evidenced by the massive bloodbath in both the stock market and across the cryptocurrency markets, with the flagship digital asset Bitcoin (BTC) now struggling to stay above $50,000.

3 stocks to counter a recession, according to ChatGPT4-o

Bristol-Myers

McDonald's

Altria

NEXTracker Inc

The market consistently offers opportunities in value stocks for bargain hunters willing to do the work and take risks. Most of the work is done here for you as I have identified value stocks that are cheaply priced.

Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Edwards Lifesciences

Glaukos

iRhythm Technologies

Inari Medical

SI-BONE Inc

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

7 Leading MedTech Stocks for Next-Gen Health Solutions

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ®  as a foundational frontline therapy in multiple myeloma with potential to significantly delay disease progression HORSHAM, Pa. , July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT).1 Patients will have the opportunity to receive this DARZALEX FASPRO ®-based quadruplet therapy at initial diagnosis, providing them with a new treatment that may significantly improve outcomes.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

Disney

The Dow Jones Industrial Average is a laggard in 2024. While other indices roared higher over the first half of the year, the venerable Dow gained only about half of its peers.

Q3's Rising Stars: 3 Dow Stocks for Your Must-Watch List

As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic, is now breaking out of a multi-year consolidation phase.

Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5th, at the Encore Boston Harbor, Evertte, MA. Tim Schmid, Executive Vice President, WorldWide Chairman, MedTech will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.

Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference

AbbVie

Amgen

AstraZeneca

Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.

Pharma companies less concerned after hearing from US on negotiated prices for Medicare

Johnson & Johnson is attempting to resolve talc lawsuits through bankruptcy for a third time. This time around, it's letting claimants vote on its proposed settlement.

Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?

Apple

Mastercard

Microsoft

Realty Income Corp

Verizon

Preparing for a recession and the next stock market decline is important as it can help you to significantly reduce the volatility of your investment portfolio. In this article, I have selected 10 companies which are particularly suitable for such a recession-proof portfolio, especially due to the companies' ability to pay sustainable dividends. All of the selected companies have a robust business model, strong competitive advantages, an excellent competitive position, and are financially healthy.

Top 10 Dividend Stocks For A Recession-Focused Portfolio In 2024

PHILADELPHIA--(BUSINESS WIRE)--Lawyers on behalf of tens of thousands of ovarian cancer victims are calling on Johnson & Johnson (NYSE: JNJ) to end its “war of attrition against cancer victims.” “The third time will not be the charm for J&J,” says Andy Birchfield, head of the Mass Torts Litigation Section at the Beasley Allen Law Firm, who has been instrumental in helping to foil the first two attempts at bankruptcy by the half-trillion-dollar company. “Recent developments in the courts.

Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan

NEW YORK--(BUSINESS WIRE)--Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson (“J&J”) (NYSE: JNJ) talcum powder settlement, leaving claimants just hours to act. Talc claimants can vote on the plan at www.OfficialTalcClaims.com or by calling 1-888-431-4056. The approximately $8 billion plan, which has a net present value of $6.475 billion, will compensate current and futu.

FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan

If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson's comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, BELGIUM, July 26, 2024 (GLOBE NEWSWIRE) --  Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the Marketing Authorisation (MA) of Yuvanci®. Yuvanci® is a single tablet combination therapy of macitentan 10 mg and tadalafil 40 mg (M/T STCT) as a substitution therapy for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, who are already treated with the combination of macitentan and tadalafil given concurrently as separate tablets.1 PAH is a rare, progressive and life-threatening disease characterised by the constriction of small pulmonary arteries and elevated blood pressure (hypertension) in the pulmonary circulation that eventually leads to right heart failure and death.2 ,3 The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) pulmonary hypertension (PH) guidelines have strengthened recommendations on initial double combination therapy with macitentan and tadalafil for PAH patients without cardiopulmonary comorbidities.4 However, this requires patients to take multiple pills as no single tablet that targets two or more PAH-specific pathways is available for these patients in Europe.

Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

Domino's Pizza

There are deals to be found in the current market. If the goal is to buy low and sell high, then investors should find lots to like among value and blue-chip stocks that have been beaten down and whose share price has been in the red over the past year.

News for Johnson & Johnson Stock (JNJ)